Want to see SE:GETI.B full AI Analyst Report?
Top Page
Getinge
(GETI.B)
Select Model
Select Model
Rating:75Outperform
Price Target:
kr262.00
▲(13.76% Upside)
Action:Reiterated
Date:07/18/26
The score is driven primarily by solid financial performance with improving profitability and strong, rebounding free cash flow, supported by clear bullish technicals (price above key moving averages and positive MACD). Valuation tempers the outlook somewhat given the P/E of 26.85, despite a ~2.04% dividend yield.
Positive Factors
Strong free cash flow
Sustained high FCF (3.8B TTM) and ~72% conversion indicate the business consistently converts earnings into cash. This supports durable uses—service network investment, product R&D, maintenance of installed base, dividends or deleveraging—improving long-term financial flexibility.
Negative Factors
Margins below pre‑pandemic peaks
Despite recent improvement, current margins remain meaningfully below 2021–2022 peaks. This suggests persistent structural pressures—mix shifts, pricing limits or cost inflation—that could cap profitability and returns until underlying structural issues are addressed.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow
Sustained high FCF (3.8B TTM) and ~72% conversion indicate the business consistently converts earnings into cash. This supports durable uses—service network investment, product R&D, maintenance of installed base, dividends or deleveraging—improving long-term financial flexibility.
Read all positive factors
Getinge (GETI.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr65.29B
Dividend Yield1.97%
Average Volume (3M)472.77K
Price to Earnings (P/E)24.4
Beta (1Y)0.78
Revenue Growth-3.56%
EPS Growth79.60%
CountrySE
Employees11,758
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)9.83
Shares Outstanding254,152,370
10 Day Avg. Volume671,507
30 Day Avg. Volume472,771
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)2.03
Price to Sales (P/S)1.70
P/FCF Ratio22.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr260.00Price Target Upside12.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)12.53
Revenue Forecast (FY)kr35.17B
Getinge Business Overview & Revenue Model
Company Description
Getinge AB, founded in 1904 and headquartered in Gothenburg, Sweden, is a prominent global supplier of medical technology solutions. The company's extensive portfolio is designed for critical healthcare environments, including operating rooms, int...
How the Company Makes Money
Getinge makes money primarily by selling medical-technology products and related services to hospitals, clinics, and life-science/pharmaceutical customers. A significant portion of revenue comes from capital equipment sales across its business are...
Getinge Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.24B | 34.97B | 34.76B | 31.83B | 28.29B | 27.05B |
| Gross Profit | 16.29B | 15.54B | 16.15B | 14.49B | 13.43B | 13.58B |
| EBITDA | 6.46B | 5.85B | 5.31B | 5.93B | 5.70B | 6.15B |
| Net Income | 2.68B | 2.26B | 1.64B | 2.41B | 2.49B | 2.97B |
Balance Sheet | ||||||
| Total Assets | 57.37B | 56.51B | 63.92B | 53.59B | 52.03B | 46.05B |
| Cash, Cash Equivalents and Short-Term Investments | 2.05B | 3.40B | 2.96B | 2.73B | 5.68B | 4.08B |
| Total Debt | 11.10B | 10.88B | 10.73B | 8.08B | 5.82B | 4.31B |
| Total Liabilities | 26.37B | 27.01B | 30.71B | 23.18B | 21.58B | 20.88B |
| Stockholders Equity | 30.95B | 29.43B | 33.01B | 30.17B | 30.04B | 24.75B |
Cash Flow | ||||||
| Free Cash Flow | 3.80B | 2.63B | 3.27B | 1.60B | 2.23B | 5.63B |
| Operating Cash Flow | 5.03B | 3.95B | 4.58B | 2.96B | 3.37B | 6.56B |
| Investing Cash Flow | -2.73B | -2.96B | -4.55B | -6.54B | -1.47B | -1.33B |
| Financing Cash Flow | -2.11B | -765.00M | 504.00M | 511.00M | -500.00M | -7.24B |
Getinge Technical Analysis
Positive
230.30
Price Trends
215.66
Positive
202.69
Positive
202.85
Positive
Market Momentum
6.84
Positive
71.26
Negative
68.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GETI.B, the sentiment is Positive. The current price of 230.3 is below the 20-day moving average (MA) of 236.60, above the 50-day MA of 215.66, and above the 200-day MA of 202.85, indicating a bullish trend. The MACD of 6.84 indicates Positive momentum. The RSI at 71.26 is Negative, neither overbought nor oversold. The STOCH value of 68.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:GETI.B.
Getinge Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr54.63B | 95.56 | 28.52% | 0.41% | 9.32% | 0.07% | |
75 Outperform | kr65.29B | 24.38 | 8.88% | 2.06% | -3.56% | 79.60% | |
71 Outperform | kr14.73B | 69.01 | 23.82% | ― | 21.08% | 44.49% | |
71 Outperform | kr8.88B | 100.21 | 4.13% | ― | 8.79% | -20.48% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | kr543.18M | -64.58 | -2.84% | ― | -13.72% | 52.47% | |
45 Neutral | kr1.09B | -30.61 | -3.99% | ― | -0.34% | 29.54% |
* General Sector Average
SE:GETI.B
Getinge
240.60
39.34
19.55%
SE:BONEX
BONESUPPORT HOLDING AB
223.60
-63.40
-22.09%
SE:XVIVO
Xvivo Perfusion AB
281.60
98.00
53.38%
SE:BACTI.B
Bactiguard Holding AB
15.20
-12.80
-45.71%
SE:SECT.B
Sectra AB Class B
283.00
-67.33
-19.22%
SE:SEDANA
Sedana Medical AB
10.36
-5.64
-35.25%
Getinge Corporate Events
Getinge Posts Strong Q2 Results and Bolsters Endoscopy, Digital Surgery Offerings
Jul 17, 2026
Getinge reported a robust second quarter, delivering 4.6% organic sales growth, 6.2% organic order intake growth and a sharp increase in profitability, with the adjusted EBITA margin rising to 17.6% and free cash flow roughly doubling year-on-year...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.